CDI Labs published three studies using CDI Labs’ HuProt™ human proteome microarray to investigate cellular targets in acute myeloid leukemia, multiple myeloma, and diffuse large B-cell lymphoma.
Published
Signal category
Research & Knowledge
Quote
“Three recent studies using CDI Labs’ HuProt™ human proteome microarray show how the same proteome-scale platform can be applied to very different research questions.”
— CDI Labs team
Company
CDI Labs
Transformational Tools and Services for Proteome-wide Autoantibody Profiling and Target Identification
- Industry
- Biotechnology Research
- Location
- Mayagüez, US
- Company size
- 40 employees
CDI Labs is a specialized CRO and lab services proteomics company powered by cutting-edge synthetic biology platforms. We have generated the world’s largest collection of proteomes, and in doing so has built a team with deep proteomics bench expertise. Our team leverages our platforms and products to offer unique services that enable customers to decipher and characterize molecular interactions across entire proteomes. Our solutions span basic research, discovery, validation and clinical deployment phases. Our services include: autoantibody biomarker discovery and profiling; viral exposure profiling; immunogenicity assessment of cell, gene and radioligand therapies; antibody and ADC specificity profiling; target identification for monoclonals, biologics and drugs; and custom protein and monoclonal antibody manufacturing for downstream validation. Our industry-leading HuProt™ array consists of over 21,000+ unique human proteins, isoform variants, and protein fragments that cover 16,794 unique genes. • Human autoantibody seromics discovery • Biomarker discovery • Protein-protein interactions • Target ID of unknown binders • Antibody specificity Now introducing PhIP-Seq – with VirScan®, HuScan® and MouseScan™ phage display libraries (by CDI Labs Canada). Join us in creating the antigen-specific revolution, and help unravel some of the greatest mysteries in human health.
Founded 2008